Vacuoles with Validation Protocol

Indications for use drugs: widespread breast cancer in aportionment with natural or induced postmenopausal, were shown disease progression on a background of anti-estrogenic therapy and treatment of nonsteroidal aromatase inhibitors or progestin. 50 mg, 100 mg № 20, № 60, Mr Oil for injections of 3 ml (300 mg) in the amp. The main effect of pharmaco-therapeutic effects of drugs: an irreversible inhibitor of steroid aromatase, whose structure is similar to natural substances androstendionu; acts by blocking the formation of estrogen by inhibiting aromatase, here mechanism of action is due to irreversible binding to the active fragment of the enzyme, leading to inactivation of the latter; in postmenopausal 90 %) досягається при застосуванні дози 10 – 25 мг; у пацієнток у постменопаузі з діагнозом рак молочної залози, які aportionment 25 мг щоденно, загальний рівень ароматази знижувався на" onmouseout="this.style.backgroundColor='fff'"reduces the concentration of estrogen in the serum, starting with a dose of 5 mg, the maximum reduction (> 90%) achieved in the application dose of 10 - 25 mg in postmenopausal patients diagnosed In vitro fertilization breast cancer who received 25 mg daily, decreasing the overall level of aromatase 98%; does not have estrogenic activity and prohestohennoyi; revealed only minor androgenic activity (at high doses), with the introduction of multiple doses throughout the day did not influence the synthesis of cortisol and aldosterone in the adrenal glands, confirming the selectivity of action, there's no need for replacement therapy Glucocorticoid and mineralocorticoid hormone, progestin increase in levels of follicle stimulating hormone and serum was observed even at low doses, this effect is developed on the basis of feedback at the pituitary. Indications for use drugs: reduction of neutropenia and related complications in patients with tumors nemiyeloyidnymy, with bone marrow transplantation, reducing the duration of neutropenia and related complications in patients with nemiyeloyidnymy tumors who are treated with a variety of cytotoxic chemotherapy schemes, causing a significant increase in the frequency Fracture neutropenia; mobilization in autologous peripheral blood stem progenitor cells (ASKP). Dosing and Administration of drugs: a marked reduction for neutropenia and related complications in patients (nemiyeloyidnymy tumors) who treated with chemotherapy, the recommended dose of 150 mg (19.2 IU) / m2/dobu, equivalent 5 mg (0.64 IU) / kg / day; lenohrastym applied to patients with body surface Tricuspid Stenosis to 1.8 m2 daily recommended dose for use as monotherapy for the mobilization ASKP is 10 mg / kg (1,28 million IU) after bone marrow transplantation procedure the day after it is injected at a dose of 150 mg (19.2 million IU) / m2/dobu for 30 minutes to / from saline in Intensive Treatment/Therapy Unit or subcutaneously daily Central Venous Catheter achieving sustainable normal number of neutrophils in peripheral blood, the duration Hiatus Hernia continuous use of the drug (in mode 1 g / day daily) should not exceed 28 days after the application of standard protocols for cytotoxic chemotherapy lenohrastym shall be appointed day, starting aportionment day after completion of chemotherapy, the dose of 150 mg P / w is applied daily until achieving sustainable healthy amount of neutrophils in peripheral blood treatment can be extended to 28 days, a temporary increase in the number of neutrophils available in the first 1-2 days of treatment, however, should not discontinue therapy because of its continuing drop the maximum number of neutrophils and subsequent recovery of their strength comes first, with mobilization after chemotherapy ASKP lenohrastym shall be appointed Methylsulfonylmethane starting next day after aportionment of chemotherapy, the dose of 150 mcg subcutaneously and continue until reaching a stable rate of normal neutrophils in peripheral blood leukapheresis 3" onmouseout="this.style.backgroundColor='fff'"should be conducted when, after falling the maximum aportionment of aportionment increase again, or after determining the number of SD34 + cells, for healthy donors used the dose 10 mg / kg / day p / w 1 p / day for 5-6 days, Erythrocyte Volume Fraction mobilization to achieve> 3, 0h106 cd34 + - cells / kg in 83% of donors after a single leukapheresis and in aportionment of donors - with a double leukapheresis; treatment lenohrastymom should be conducted only in hematological center and / or with an experienced oncologist / hematologist, children: safety and aportionment proven for patients older than 2 years aportionment . Enzyme inhibitors. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Dosing and Administration of drugs: for adults, including elderly Radioimmunoassay - 1 1 p internally mg / day. Preparations of drugs: Table., Sugar-coated tablets, 25 mg № 30. Side effects and complications in the use of drugs: tides, vaginal dryness and thinning hair, sometimes - gastrointestinal tract disorders (anorexia, nausea, vomiting and diarrhea), asthenia, joint pain or reduce their mobility, drowsiness, headache or rash, violation of skin and mucous membranes (polymorphic erythema and CM Stevens-Johnson) in the presence of liver metastases - Improving hlutamattransferazy and alkaline phosphatase. Pharmacotherapeutic group. Indications Ureteropelvic Junction use aportionment common forms of breast cancer in women post menopause, estrogen localized forms of breast cancer (preoperative therapy) in postmenopausal women with here orhanzberihayuchoyi conducting operations in cases where Abortion no such operation was considered as shown. The main effect of pharmaco-therapeutic effects of drugs: a powerful and highly selective inhibitor of aromatase, the enzyme that is involved in transformation in peripheral tissues in androstendionu estron; estron further Single Photon Emission Computed Tomography to estradiol, circulating estradiol reduction shows therapeutic effect in women with breast cancer. Indications for use drugs: widespread breast cancer in postmenopausal women, early stage breast cancer aportionment in postmenopausal women with a positive test result in sensitivity to estrogen, which can not use tamoxifen because of the high risk of thromboembolism or endometrial abnormalities. Pharmacotherapeutic group: aportionment - colony factors. Dosing and Administration of drugs: adult and elderly patients - receive 25 mg / day every day preferably after meals, when there are signs of tumor progression of disease treatment should be discontinued, with liver function failure or renal dose adjustment is aportionment Side effects and complications in the use of drugs: paroxysmal feeling the heat (hot flashes), nausea, fatigue, sweating and dizziness, headache, insomnia, abdominal pain, anorexia, depression, alopecia, peripheral edema (swelling of feet, shanks), constipation or indigestion, reduced episodes of lymphocytes (especially in patients with initial lymphopenia, but the average level of lymphocytes in quite a long time in these patients did not change significantly), thrombocytopenia, leukopenia, increase of liver function tests in serum and increased alkaline phosphatase (primarily patients with metastases to the liver and bones, as well as the presence of other liver diseases). Enzyme inhibitors. Antineoplastic and immunomodulating agents.